Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOLDOPAM MESYLATE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
In-hospital, short-term (up to 48 hours) management of severe hypertension (hypertensive crisis) when rapid, but quickly reversible, blood pressure reduction is required,Off-label: Management of hypertensive emergencies with acute renal impairment
Hypertension
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily hepatic via conjugation (glucuronidation and sulfation); CYP450 minimally involved.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 90% bound to plasma proteins, primarily albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.6–0.8 L/kg; moderate distribution consistent with limited tissue penetration.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Intravenous: 100%; no oral bioavailability due to extensive first-pass metabolism (not administered orally).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dose adjustment required for renal impairment; however, monitor for hypotension and electrolyte disturbances.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to increased risk of hypotension.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not FDA-approved for pediatric use; limited data: 0.2 mcg/kg/min IV infusion, titrated to effect; max 0.8 mcg/kg/min.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at low end of dosing range (0.1 mcg/kg/min) due to increased sensitivity to hypotension; monitor blood pressure closely.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
No FDA black box warning.
None
Hypotension risk: Monitor blood pressure closely; may cause excessive hypotension.,Tachycardia: Can increase heart rate; caution in patients with coronary ischemia or tachyarrhythmias.,Glaucoma risk: May increase intraocular pressure; avoid in patients with glaucoma.,Hypokalemia: Monitor potassium levels; may cause hypokalemia.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Known hypersensitivity to fenoldopam or any component,Patients with glaucoma
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
No specific food interactions reported. However, patients should avoid excessive caffeine or stimulants as they may affect blood pressure.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for fetal hypotension and decreased uteroplacental perfusion; use only if clearly needed. Avoid in severe preeclampsia or eclampsia due to risk of significant maternal hypotension.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
No data on presence in human milk; M/P ratio unknown. Caution advised; consider benefits of breastfeeding vs potential risk of infant exposure.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No standard dose adjustments required; but use lowest effective dose due to increased sensitivity to hypotensive effects in pregnancy. Titrate carefully.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Fenoldopam is a dopamine D1-like receptor agonist used for severe hypertension and hypertensive emergencies. It causes rapid, titratable blood pressure reduction without the toxic metabolites seen with nitroprusside. It also increases renal blood flow and natriuresis, making it beneficial in patients with renal impairment. Avoid in patients with glaucoma (increases intraocular pressure) or sulfite allergy (contains sodium metabisulfite).
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
This medication is given intravenously and is only used in a hospital setting.,You will have your blood pressure and heart rate monitored continuously during the infusion.,Report any headache, flushing, or dizziness to your nurse.,Do not stop the infusion suddenly; the dose will be gradually decreased.,Avoid consuming caffeine or other stimulants during treatment.,Tell your healthcare provider if you have glaucoma or a history of sulfite allergy.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
"Fenoldopam, a dopamine D1-like receptor agonist used for in-hospital blood pressure reduction, can potentiate the hypotensive and hypovolemic effects of the loop diuretic ethacrynic acid. Ethacrynic acid induces sodium and water diuresis, leading to reduced intravascular volume; Fenoldopam causes arterial vasodilation. When co-administered, the combined hemodynamic stress may increase the risk of excessive hypotension, renal hypoperfusion, and acute kidney injury, particularly in patients with compromised cardiac output or volume depletion."
"Iloprost, a prostacyclin analog, enhances vasodilation and inhibits platelet aggregation via IP receptor activation, increasing intracellular cAMP. Fenoldopam, a selective dopamine D1 receptor agonist, induces systemic and renal vasodilation through cAMP-dependent pathways. Concomitant use amplifies the hypotensive effect, potentially leading to severe hypotension, reflex tachycardia, and end-organ hypoperfusion, especially in patients with compromised cardiovascular reserve."
"Amlodipine, a dihydropyridine calcium channel blocker, reduces peripheral vascular resistance by inhibiting calcium influx into vascular smooth muscle cells. Fenoldopam, a selective dopamine D1 receptor agonist, causes arterial vasodilation, particularly in the renal and mesenteric beds. The concurrent use of these two vasodilatory agents leads to additive hypotension, potentially causing symptomatic drops in blood pressure, dizziness, and syncope, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOLDOPAM MESYLATE vs ALDORIL D30, answered by our medical review team.
FENOLDOPAM MESYLATE is a Antihypertensive that works by Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOLDOPAM MESYLATE and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOLDOPAM MESYLATE is: 0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOLDOPAM MESYLATE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOLDOPAM MESYLATE is classified as Category C. Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for feta. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.